In the course of the RAC meeting, the researchers were confronted with data re- 
quests that were frankly irresponsible. For example, they were asked to produce 
experimental evidence that diluting an aliquot by a factor of ten lowers its con- 
centration by a factor of ten. 
I can understand that the human gene therapy subcommittee would want to take 
its time reviewing the first case of genetic intervention in humans. But they 
should have the discipline to resist the temptation when there are no real issues 
to think about. Being first makes this experiment newsworthy, but it does not 
make it an ethical dilemma. Indeed, I felt that the only ethical choice the RAC 
could make was an immediate approval. 
The RAC did not make its decision carelessly. After hearing the details of the 
proposal, and listening to the concerns of the subcommittee, the majority felt that 
the researchers and MH deserved congratulations and encouragement— not 
more delays. I urge you to proceed with all due speed. 
Respectfully yours, 
Brian F. Mannix 
Member, Recombinant-DNA 
Advisory Committee 
c: RAC members 
Recombinant DNA Research, Volume 13 
[449] 
